𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma

✍ Scribed by Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
115 KB
Volume
24
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2‐[^18^ F] fluoro‐2‐deoxy‐D‐glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC.

Methods

Between 1993 and 1999 47 patients underwent PET before (PET~1~) and after (PET~2~) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow‐up time was 3.3 years.

Results

Low and high MR FDG at PET~2~, with median value as cutoff, was associated with complete remission in 96% and 62% (p = .007), with 5‐year overall survival in 72% and 35% (p = .0042) and with local control in 96% and 55% (p = .002), respectively.

Conclusions

FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. © 2002 John Wiley & Sons, Inc.

📜 SIMILAR VOLUMES

Targeted therapies in squamous cell carc
Targeted therapies in squamous cell carcinoma of the head and neck
✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r

Efficacy of neck treatment in patients w
Efficacy of neck treatment in patients with head and neck squamous cell carcinoma
✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the

Treatment of the N0 neck during salvage
Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma
✍ Stephane Temam; Venkata Koka; Gérard Mamelle; Morbize Julieron; Romain Carmantra 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Background. The morbidity and mortality rates of salvage surgery in patients with local recurrence of head and neck squamous cell carcinoma (HNSCC) after radiotherapy are high. The aim of this study was to determine the rate of occult neck node metastasis and the surgical morbidity of patients after

Molecular markers predict outcome in squ
Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation
✍ Guido B. van den Broek; Maarten Wildeman; Coen R.N. Rasch; Nicola Armstrong; Ed 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB 👁 1 views

## Abstract Not all patients with squamous cell carcinomas of the head and neck (HNSCC) benefit from concurrent cisplatin‐based chemoradiation, but reliable predictive markers for outcome after chemoradiation are scarce. We have investigated potential prognostic biomarkers for outcome in a large gr